Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples

Abstract Compared to other infectious diseases, for which LFT development can take years, SARS-CoV-2 antigen LFTS were developed and deployed within months. LFTS for antigen detection were adopted on an unprecedented scale during the COVID-19 pandemic, but many of them lack the sensitivity especiall...

Full description

Bibliographic Details
Main Authors: Manal Kamel, Shimaa Atta, Sara Maher, Hesham Abd Elaziz, Zeinab Demerdash
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-024-57230-8
_version_ 1797233601377468416
author Manal Kamel
Shimaa Atta
Sara Maher
Hesham Abd Elaziz
Zeinab Demerdash
author_facet Manal Kamel
Shimaa Atta
Sara Maher
Hesham Abd Elaziz
Zeinab Demerdash
author_sort Manal Kamel
collection DOAJ
description Abstract Compared to other infectious diseases, for which LFT development can take years, SARS-CoV-2 antigen LFTS were developed and deployed within months. LFTS for antigen detection were adopted on an unprecedented scale during the COVID-19 pandemic, but many of them lack the sensitivity especially for samples with low viral load. In our previous work, we developed an enhanced signal strip for detection of SARS CoV-2 SI antigens in saliva. Here we introduce some modification to improve the sensitivity, and specificity, and to lower the cost of the strip, by using biotin streptavidin (BS) system. In the modified BS strip, gold-streptavidin and biotinylated Nanobodies (Nbs) against S1 antigen were externally mixed with the tested samples (saliva or nasopharyngeal swab) before their application on the sample pad of the test strip containing angiotensin converting enzyme (ACE-2), as the capturing probe. The study included 320 individuals, with 180 being positively confirmed by RT-PCR and 140 confirmed negative, as well as, 45 health care workers, who were responsible for screening and handling of surgical cases in General Surgery Department and COVID clinic of TBRI. Our results proved that modified BS strip improved the overall sensitivity and specificity of S1antigen detection in saliva samples (95.21% and 99.29% respectively) compared to our previously developed enhanced LFTS (91.66% and 98.57% respectively). Also, the sensitivity of cases with Ct ≤ 30, Ct $$\le$$ ≤ 35, and Ct $$\le$$ ≤ 40 using the modified BS strip showed higher values (98.54%, 95.38%, and 88.89% respectively), compared to the corresponding results of our previously developed enhanced LFTS (95.86%, 92.31%, and 82.22% respectively). There were no cross-reactions with either Middle East respiratory syndrome corona virus MERS-CoV or SARS-CoV antigens. Furthermore, we found that the lower viral detection limit (LVD) of BS strip was obviously lower than our previous LVD limit of the enhanced LFTS (0.2 × 104 copies/ml vs. 0.4 × 104 copies/ml, respectively). Our developed BS strip showed that saliva samples gave better results than nasopharyngeal swabs of the same patients. The fact of using smaller amounts of Nbs, and ACE2, as well as the dispensing off of conjugate pad when applying BS strip modifications, justified the expected reduction in the costs of the strip. The implementation of BS strips on saliva samples of 45 health co-workers, who were tested 4 and 6 days after exposure to infection, showed an increase in the sensitivity, starting from the 4th day and reaching its highest level on the 6th day in both high risk and paramedic groups (90.9%, and 80.0%, respectively). This study provides evidence that employment of the modified BS system could increase the sensitivity of the strips, lower their cost, and render them an effective screening tool for early detection of the virus in saliva of suspected Covid-19 patients.
first_indexed 2024-04-24T16:18:46Z
format Article
id doaj.art-84320e7243864f46822ad92bbab49108
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-24T16:18:46Z
publishDate 2024-03-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-84320e7243864f46822ad92bbab491082024-03-31T11:18:37ZengNature PortfolioScientific Reports2045-23222024-03-0114111210.1038/s41598-024-57230-8Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samplesManal Kamel0Shimaa Atta1Sara Maher2Hesham Abd Elaziz3Zeinab Demerdash4Immunology Department, Theodor Bilharz Research InstituteImmunology Department, Theodor Bilharz Research InstituteImmunology Department, Theodor Bilharz Research InstituteSurgery Department, Theodor Bilharz Research InstituteImmunology Department, Theodor Bilharz Research InstituteAbstract Compared to other infectious diseases, for which LFT development can take years, SARS-CoV-2 antigen LFTS were developed and deployed within months. LFTS for antigen detection were adopted on an unprecedented scale during the COVID-19 pandemic, but many of them lack the sensitivity especially for samples with low viral load. In our previous work, we developed an enhanced signal strip for detection of SARS CoV-2 SI antigens in saliva. Here we introduce some modification to improve the sensitivity, and specificity, and to lower the cost of the strip, by using biotin streptavidin (BS) system. In the modified BS strip, gold-streptavidin and biotinylated Nanobodies (Nbs) against S1 antigen were externally mixed with the tested samples (saliva or nasopharyngeal swab) before their application on the sample pad of the test strip containing angiotensin converting enzyme (ACE-2), as the capturing probe. The study included 320 individuals, with 180 being positively confirmed by RT-PCR and 140 confirmed negative, as well as, 45 health care workers, who were responsible for screening and handling of surgical cases in General Surgery Department and COVID clinic of TBRI. Our results proved that modified BS strip improved the overall sensitivity and specificity of S1antigen detection in saliva samples (95.21% and 99.29% respectively) compared to our previously developed enhanced LFTS (91.66% and 98.57% respectively). Also, the sensitivity of cases with Ct ≤ 30, Ct $$\le$$ ≤ 35, and Ct $$\le$$ ≤ 40 using the modified BS strip showed higher values (98.54%, 95.38%, and 88.89% respectively), compared to the corresponding results of our previously developed enhanced LFTS (95.86%, 92.31%, and 82.22% respectively). There were no cross-reactions with either Middle East respiratory syndrome corona virus MERS-CoV or SARS-CoV antigens. Furthermore, we found that the lower viral detection limit (LVD) of BS strip was obviously lower than our previous LVD limit of the enhanced LFTS (0.2 × 104 copies/ml vs. 0.4 × 104 copies/ml, respectively). Our developed BS strip showed that saliva samples gave better results than nasopharyngeal swabs of the same patients. The fact of using smaller amounts of Nbs, and ACE2, as well as the dispensing off of conjugate pad when applying BS strip modifications, justified the expected reduction in the costs of the strip. The implementation of BS strips on saliva samples of 45 health co-workers, who were tested 4 and 6 days after exposure to infection, showed an increase in the sensitivity, starting from the 4th day and reaching its highest level on the 6th day in both high risk and paramedic groups (90.9%, and 80.0%, respectively). This study provides evidence that employment of the modified BS system could increase the sensitivity of the strips, lower their cost, and render them an effective screening tool for early detection of the virus in saliva of suspected Covid-19 patients.https://doi.org/10.1038/s41598-024-57230-8StreptavidinBiotinNanobodiesSARS-CoV-2 S1SalivaRapid test
spellingShingle Manal Kamel
Shimaa Atta
Sara Maher
Hesham Abd Elaziz
Zeinab Demerdash
Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples
Scientific Reports
Streptavidin
Biotin
Nanobodies
SARS-CoV-2 S1
Saliva
Rapid test
title Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples
title_full Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples
title_fullStr Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples
title_full_unstemmed Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples
title_short Modified streptavidin–biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples
title_sort modified streptavidin biotin based lateral flow test strip for rapid detection of sars cov 2 s1 antigen in saliva samples
topic Streptavidin
Biotin
Nanobodies
SARS-CoV-2 S1
Saliva
Rapid test
url https://doi.org/10.1038/s41598-024-57230-8
work_keys_str_mv AT manalkamel modifiedstreptavidinbiotinbasedlateralflowteststripforrapiddetectionofsarscov2s1antigeninsalivasamples
AT shimaaatta modifiedstreptavidinbiotinbasedlateralflowteststripforrapiddetectionofsarscov2s1antigeninsalivasamples
AT saramaher modifiedstreptavidinbiotinbasedlateralflowteststripforrapiddetectionofsarscov2s1antigeninsalivasamples
AT heshamabdelaziz modifiedstreptavidinbiotinbasedlateralflowteststripforrapiddetectionofsarscov2s1antigeninsalivasamples
AT zeinabdemerdash modifiedstreptavidinbiotinbasedlateralflowteststripforrapiddetectionofsarscov2s1antigeninsalivasamples